Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study

Admassie, Endalkachew; Chalmers, Leanne; Bereznicki, Lre

doi:10.1007/s00228-017-2337-9

Cited by 4 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By reviewing the title and abstract, 19 remaining studies were potentially available, and further assessed under the full-text screenings. According to the pre-defined inclusion and exclusion criteria, we subsequently excluded 7 studies because (1) article is a meta-analysis (n=1) [16]; (2) studies did not report the relevant outcomes (n=3) [17][18][19]; (3) studies did not report the classification of polypharmacy (n=3) [20][21][22]. Finally, a total of 12 studies were included in our meta-analysis [8-10, 15, 23-30].…”

Section: Resultsmentioning

confidence: 99%

Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis

Zheng

Li²,

Liu³

et al. 2023

Preprint

View full text Add to dashboard Cite

Aims: The aim of the present meta-analysis was to evaluate the effectiveness and safety of non–vitamin K antagonist oral anticoagulants (NOACs) vs. vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with polypharmacy. Methods and results: Randomized controlled trials or observational studies reporting the data about the NOACs and VKAs therapy among AF patients with polypharmacy were included. The search was performed in the PubMed and Embase databases up to November 2022. There were no differences in the rates of SSE but increased risk of all-cause death and major bleeding between moderate polypharmacy and severe polypharmacy versus no-polypharmacy patients. The use of NOACs compared with VKAs was significantly associated with reduced risks of stroke or systemic embolism (SSE) in AF patients with moderate polypharmacy (hazard ratios [HRs], 0.77 [95% confidence intervals [CIs], 0.69–0.86]) and severe polypharmacy (HR, 0.76 [95% CI, 0.69–0.82]) and there was no significant difference in major bleeding (moderate polypharmacy: HR, 0.87 [95% CI, 0.74–1.01]; severe polypharmacy: HR, 0.91 [95% CI, 0.79–1.06]) between the two groups. There were no differences in the rates of ischemic stroke, all-cause death, and gastrointestinal bleeding but reduced risk of any bleeding between the NOACs and VKAs users. Compared with VKAs, the risk of intracranial hemorrhage was reduced in patients with moderate polypharmacy but not in patients with severe polypharmacy in NOACs users. Conclusion: In patients with AF and polypharmacy, NOACs showed advantages over VKAs in SSE and bleeding, and non-inferiority in major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis

Zheng

Li²,

Liu³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…9 However, varying incidence of major bleeding was noted in a tertiary care academic center in Minneapolis (5.2 per 100 patient-years) 10 and in a large Tasmania referral hospital (2.4 per 100 patient-years). 11 Patients admitted for warfarin-related AEs in our study were mostly elderly with a mean age of 66.1 years (95% confidence interval of 64.6 -67.7). However, increasing age did not correlate with the severity of bleeding or death, as also stipulated by Ozturk et al 12 Patients admitted for warfarinrelated AEs were reported as elderly in few studies with median age of population studied ranged from 61 to 65 years.…”

Section: Discussionmentioning

confidence: 86%

“…Documented possible reasons for warfarin-related AEs are presented in Table 3. The most common causes of warfarin-related AEs were the use of analgesia within 1 week (13), medication error (11), and use of traditional medication within 1 week (6). The majority of the medication error (7/11) cases were due to patients taking unintentional wrong doses.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital

et al. 2022

View full text Add to dashboard Cite

Introduction: Oral anticoagulant is essential for the treatment and prevention of thromboembolism. Warfarin is an effective oral anticoagulant in prevention and treatment of thromboembolism. However, warfarin is frequently associated with adverse event (AE) requiring hospitalization. Method: We performed a retrospective cohort study of all patients admitted to a large tertiary public hospital for warfarin-related AEs. Patients were grouped based on bleeding severity and the direct medical cost was also calculated. Results: During the 4 years study period, a total of 224 patients were admitted for warfarin-related AEs. Mean age of patients admitted was 65.1 years (standard deviation [SD] = 11.5). More than half, 59.6%, of them were on warfarin for prevention of stroke in atrial fibrillation or atrial flutter. Major bleeding occurred among 50.9% of the patients with gastrointestinal bleed, 34 (29.8%), as the common site of bleed. Patients with major bleed had longer median hospital stay of 4 days (interquartile range [IQR] = 5) compared to 3 (IQR = 3) days in non-major bleed. There were 17 (14.9%) death among the major bleeders. Mean medical cost for managing warfarin-related AEs was USD 708.08. Conclusion: The admitted patients were equally distributed in terms of bleeding severity. Medical cost incurred for managing warfarin-related AEs increased with the severity of bleeding.

show abstract

“…9,10 The Tasmanian AF study was established in 2012 to monitor prescribing trends and patient outcomes in Tasmania, Australia, over time. 4,11,12 In this analysis, we aimed to investigate the impact of the availability of DOACs on the TE-related readmissions of patients with AF. Our specific objectives were: (1) to compare TE and mortality rates in patients commenced on antithrombotic therapy prior to and following the availability of DOACs and (2) to identify factors that influenced the risk of incident thromboembolism and all-cause mortality in patients with AF.…”

Section: Introductionmentioning

confidence: 99%

Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study

Admassie

Chalmers

Bereznicki

2018

J Cardiovasc Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study

Cited by 4 publications

References 42 publications

Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis

Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis

Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital

Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study

Contact Info

Product

Resources

About